Characterizing progression to subsequent lines of therapy in metastatic renal cell carcinoma (mRCC) after nivolumab plus ipilimumab (Nivo plus Ipi): Results from the International mRCC Database Consortium (IMDC).

被引：0
|
作者：
Lemelin, Audreylie
Takemura, Kosuke
Ernst, Matthew Scott
Wells, J. Connor
Donskov, Frede
Porta, Camillo
de Velasco, Guillermo
Davis, Ian D.
Wood, Lori
Pal, Sumanta Kumar
Hansen, Aaron Richard
Kollmannsberger, Christian K.
Bjarnason, Georg A.
Tran, Ben
Li, Haoran
Kanesvaran, Ravindran
Powles, Thomas
McKay, Rana R.
Choueiri, Toni K.
Heng, Daniel Yick Chin
机构：
[1] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[2] BC Canc Agcy, Vancouver, BC, Canada
[3] Univ Hosp Southern Denmark, Esbjerg, Denmark
[4] Univ Bari, Bari, Italy
[5] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
[6] Monash Univ, Eastern Hlth Clin Sch, Melbourne, Vic, Australia
[7] Eastern Hlth, Melbourne, Vic, Australia
[8] Dalhousie Univ, Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada
[9] City Hope Natl Med Ctr, Duarte, CA USA
[10] Univ Toronto, Div Med Oncol & Hematol, Princess Margaret Canc Ctr, Toronto, ON, Canada
[11] Univ British Columbia, Dept Med, British Columbia Canc Agcy, Vancouver, BC, Canada
[12] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[13] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[14] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[15] Natl Canc Ctr Singapore, Singapore, Singapore
[16] Queen Mary Univ London, Barts Canc Inst, London, England
[17] Univ Calif San Diego Hlth, Moores Canc Ctr, San Diego, CA USA
[18] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4538
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC)-an International mRCC Database Consortium (IMDC) analysis
    Araujo, Daniel, V
    Wells, J. Connor
    Hansen, Aaron R.
    Dizman, Nazli
    Pal, Sumanta K.
    Beuselinck, Benoit
    Donskov, Frede
    Gan, Chun L.
    Yan, Flora
    Tran, Ben
    Kollmannsberger, Christian K.
    de Velasco, Guillermo
    Yuasa, Takeshi
    Reaume, M. Neil
    Ernst, D. Scott
    Powles, Thomas
    Bjarnason, Georg A.
    Choueiri, Toni K.
    Heng, Daniel Y. C.
    Dudani, Shaan
    [J]. JOURNAL OF GERIATRIC ONCOLOGY, 2021, 12 (05) : 820 - 826
  • [32] First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An analysis from the International mRCC Database Consortium
    Harshman, Lauren Christine
    Wood, Lori
    Srinivas, Sandy
    Heng, Daniel Yick Chin
    Choueiri, Toni K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [33] Impact of bone and liver metastases (BM, LM) in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents (MTAs): Results from the International mRCC Database Consortium (IMDC)
    McKay, Rana R.
    Kroeger, Nils
    Xie, Wanling
    Lee, Jae-Lyun
    Knox, Jennifer J.
    Bjarnason, Georg A.
    MacKenzie, Mary J.
    Wood, Lori
    Srinivas, Sandy
    Vaishampayan, Ulka N.
    Rha, Sun Young
    Pal, Sumanta Kumar
    Donskov, Frede
    Tantravahi, Srinivas
    Rini, Brian I.
    Heng, Daniel Yick Chin
    Choueiri, Toni K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [34] Cabozantinib real-world effectiveness in the first through fourth-line settings for the treatment of metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)
    Gan, Chun Loo
    Dudani, Shaan
    Wells, Connor
    Donskov, Frede
    Pal, Sumanta K.
    Dizman, Nazli
    Rathi, Nityam
    Beuselinck, Benoit
    Yan, Flora
    Lalani, Aly-Khan A.
    Hansen, Aaron Richard
    Szabados, Bernadett
    de Velasco, Guillermo
    Tran, Ben
    Lee, Jae-Lyun
    Vaishampayan, Ulka N.
    Bjarnason, Georg A.
    Subasri, Mathushan
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [35] Real world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Stukalin, Igor
    Wells, J. Connor
    Graham, Jeffrey
    Yuasa, Takeshi
    Beuselinck, Benoit
    Kollmannsberger, Christian K.
    Ernst, D. Scott
    Agarwal, Neeraj
    Le, Tri
    Donskov, Frede
    Hansen, Aaron Richard
    Bjarnason, Georg A.
    Srinivas, Sandy
    Wood, Lori
    Alva, Ajjai Shivaram
    Kanesvaran, Ravindran
    Fu, Simon Yuen Fai
    Davis, Ian D.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [36] Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC): An international mRCC database consortium (IMDC) analysis.
    Araujo, Daniel Vilarim
    Wells, Connor
    Hansen, Aaron Richard
    Dizman, Nazli
    Pal, Sumanta K.
    Beuselinck, Benoit
    Donskov, Frede
    Gan, Chun Loo
    Yan, Flora
    Tran, Ben
    Kollmannsberger, Christian K.
    de Velasco, Guillermo
    Yuasa, Takeshi
    Reaume, M. Neil
    Ernst, D. Scott
    Powles, Thomas
    Bjarnason, Georg A.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    Dudani, Shaan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] First-line (1L) immuno-oncology (10) combination therapies in metastatic renal-cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC).
    Dudani, Shaan
    Graham, Jeffrey
    Wells, Connor
    Bakouny, Ziad
    Pal, Sumanta K.
    Dizman, Nazli
    Donskov, Frede
    Porta, Camillo
    de Velasco, Guillermo
    Hansen, Aaron Richard
    Iafolla, Marco Adelmo James
    Beuselinck, Benoit
    Vaishampayan, Ulka N.
    Wood, Lori
    Liow, Elizabeth Chien Hern
    Yan, Flora
    Yuasa, Takeshi
    Bjarnason, Georg A.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [38] Outcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
    Gan, Chun Loo
    Dudani, Shaan
    Wells, Connor J.
    Schmidt, Andrew Lachlan
    Bakouny, Ziad
    Szabados, Bernadett
    Parnis, Francis
    Wong, Shirley
    Lee, Jae-Lyun
    de Velasco, Guillermo
    Pal, Sumanta K.
    Davis, Ian D.
    Kanesvaran, Ravindran
    Wood, Lori
    Kollmannsberger, Christian K.
    McKay, Rana R.
    Beuselinck, Benoit
    Donskov, Frede
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [39] Synchronous metastatic renal cell carcinoma (mRCC) treated with nivolumab and ipilimumab (N plus I) and the primary tumour (PT) in place
    Meerveld-Eggink, A.
    Graafland, N.
    Wilgenhof, S.
    Van Thienen, J. V.
    Grant, M.
    Szabados, B. E.
    Abu-Ghanem, Y.
    Boleti, E.
    Blank, C. U.
    Haanen, J. B. A. G.
    Powles, T. B.
    Bex, A.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S575 - S575
  • [40] Optimizing ipilimumab in RCC: Results from SAKK 07/17 (CM-980) nivolumab (N) plus ipilimumab (Ipi) in mRCC
    Stenner-Liewen, F.
    Cathomas, R.
    Rothermundt, C. A.
    Beyer, J.
    Mach, N.
    Zihler, D.
    Erdmann, A. A.
    Kueng, M.
    Dietrich, D.
    Garzon, J. Glaus
    Lorch, A.
    Berthold, D. R.
    Laubli, H.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1209 - S1209
12345